71 related articles for article (PubMed ID: 24300920)
1. Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
Ling Y; Wang Z; Zhu H; Wang X; Zhang W; Wang X; Chen L; Huang Z; Zhang Y
Bioorg Med Chem; 2014 Jan; 22(1):374-80. PubMed ID: 24300920
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.
Ling Y; Wang X; Zhu H; Wang Z; Xu C; Wang X; Chen L; Zhang W
Arch Pharm (Weinheim); 2014 May; 347(5):327-33. PubMed ID: 24435839
[TBL] [Abstract][Full Text] [Related]
3. Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities.
Ling Y; Wang Z; Wang X; Li X; Wang X; Zhang W; Dai H; Chen L; Zhang Y
Chem Biol Drug Des; 2015 Feb; 85(2):145-52. PubMed ID: 25043275
[TBL] [Abstract][Full Text] [Related]
4. Novel FTS-diamine/cinnamic acid hybrids inhibit tumor cell proliferation and migration and promote apoptosis via blocking Ras-related signaling in vitro.
Ling Y; Zhao X; Li X; Wang X; Yang Y; Wang Z; Wang X; Zhang J; Zhang Y
Cancer Chemother Pharmacol; 2015 Feb; 75(2):381-92. PubMed ID: 25542266
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF-κB.
Ling Y; Wang Z; Wang X; Zhao Y; Zhang W; Wang X; Chen L; Huang Z; Zhang Y
Org Biomol Chem; 2014 Jul; 12(25):4517-30. PubMed ID: 24848877
[TBL] [Abstract][Full Text] [Related]
6. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
[TBL] [Abstract][Full Text] [Related]
7. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
Ling Y; Ye X; Ji H; Zhang Y; Lai Y; Peng S; Tian J
Bioorg Med Chem; 2010 May; 18(10):3448-56. PubMed ID: 20435479
[TBL] [Abstract][Full Text] [Related]
9. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
[TBL] [Abstract][Full Text] [Related]
10. Ras chaperones: new targets for cancer and immunotherapy.
Kloog Y; Elad-Sfadia G; Haklai R; Mor A
Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
[TBL] [Abstract][Full Text] [Related]
11. Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.
Ling Y; Wang X; Wang C; Xu C; Zhang W; Zhang Y; Zhang Y
ChemMedChem; 2015 Jun; 10(6):971-6. PubMed ID: 25882299
[TBL] [Abstract][Full Text] [Related]
12. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
[TBL] [Abstract][Full Text] [Related]
13. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
14. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
Santen RJ; Lynch AR; Neal LR; McPherson RA; Yue W
Anticancer Drugs; 2006 Jan; 17(1):33-40. PubMed ID: 16317288
[TBL] [Abstract][Full Text] [Related]
15. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
16. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Wu L; Pang Y; Qin G; Xi G; Wu S; Wang X; Chen T
PLoS One; 2017; 12(2):e0171840. PubMed ID: 28182780
[TBL] [Abstract][Full Text] [Related]
17. Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.
Guan Y; Zhang Y; Xiao L; Li J; Wang JP; Chordia MD; Liu ZQ; Chung LW; Yue W; Pan D
Mol Pharm; 2017 Jan; 14(1):1-13. PubMed ID: 26992462
[TBL] [Abstract][Full Text] [Related]
18. Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice.
Huang QJ; Liao GC; Zhuang XR; Yang ML; Yao JJ; Deng JH; Zhang YM; Wang Y; Qi XX; Pan DF; Guan Y; Huang ZY; Zhang FX; Liu ZQ; Lu LL
Acta Pharmacol Sin; 2022 Jul; 43(7):1843-1856. PubMed ID: 34845369
[TBL] [Abstract][Full Text] [Related]
19. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
20. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Jansen B; Heere-Ress E; Schlagbauer-Wadl H; Halaschek-Wiener J; Waltering S; Moll I; Pehamberger H; Marciano D; Kloog Y; Wolff K
J Mol Med (Berl); 1999 Nov; 77(11):792-7. PubMed ID: 10619439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
